BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

NEXT STORY
Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
PREV STORY
Principia Biopharma Appoints John W. Smither to Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

author_avatar
NASDAQ Market News

Versartis Reports Fourth Quarter and Full Year 2015 Financial Results

MENLO PARK, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

author_avatar
NASDAQ Market News

Anima Biotech To Participate In Fireside Chat During The Undruggable Leaders Forum

author_avatar
NASDAQ Market News